MORRISVILLE, N.C.--(BUSINESS WIRE)-- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary ...
Patent is expected to provide additional intellectual property protection until 2040 Prevalence estimates indicate that PH-HFpEF affects over 1,500,000 patients in the U.S. There are currently no FDA ...
provide U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond 2040 broaden IP protection for oral (TNX-103), IV, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results